Fusen Pharmaceutical Company Limited (1652.HK)

HKD 0.3

(13.46%)

Revenue Summary of Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical Company Limited's latest annual revenue in 2023 was 565.6 Million CNY , up 15.02% from previous year.
Fusen Pharmaceutical Company Limited's latest quarterly revenue in 2024 Q2 was 98.16 Million CNY , down 0.0% from previous quarter.
Fusen Pharmaceutical Company Limited reported a annual revenue of 491.75 Million CNY in annual revenue 2022, up 27.51% from previous year.
Fusen Pharmaceutical Company Limited reported a annual revenue of 385.66 Million CNY in annual revenue 2021, down -20.78% from previous year.
Fusen Pharmaceutical Company Limited reported a quarterly revenue of 98.16 Million CNY for 2024 Q1, down -14.33% from previous quarter.
Fusen Pharmaceutical Company Limited reported a quarterly revenue of 168.21 Million CNY for 2023 Q1, up 3.16% from previous quarter.

Annual Revenue Chart of Fusen Pharmaceutical Company Limited (2023 - 2015)

Historical Annual Revenue of Fusen Pharmaceutical Company Limited (2023 - 2015)

Year	Revenue	Revenue Growth
2023	565.6 Million CNY	15.02%
2022	491.75 Million CNY	27.51%
2021	385.66 Million CNY	-20.78%
2020	486.85 Million CNY	19.51%
2019	407.38 Million CNY	-11.83%
2018	462.06 Million CNY	2.09%
2017	452.58 Million CNY	2.4%
2016	441.98 Million CNY	19.9%
2015	368.63 Million CNY	0.0%

Year	Revenue	Revenue Growth
2024 Q2	98.16 Million CNY	0.0%
2024 Q1	98.16 Million CNY	-14.33%
2023 Q1	168.21 Million CNY	3.16%
2023 Q4	114.58 Million CNY	0.0%
2023 FY	565.6 Million CNY	15.02%
2023 Q2	168.21 Million CNY	0.0%
2023 Q3	114.58 Million CNY	-31.88%
2022 Q1	82.8 Million CNY	-3.41%
2022 FY	491.75 Million CNY	27.51%
2022 Q3	163.07 Million CNY	96.93%
2022 Q2	82.8 Million CNY	0.0%
2022 Q4	163.07 Million CNY	0.0%
2021 Q2	107.1 Million CNY	0.0%
2021 Q3	85.72 Million CNY	-19.96%
2021 FY	385.66 Million CNY	-20.78%
2021 Q4	85.72 Million CNY	0.0%
2021 Q1	107.1 Million CNY	-10.5%
2020 Q4	119.67 Million CNY	0.0%
2020 Q2	123.75 Million CNY	0.0%
2020 FY	486.85 Million CNY	19.51%
2020 Q1	123.75 Million CNY	17.33%
2020 Q3	119.67 Million CNY	-3.29%
2019 FY	407.38 Million CNY	-11.83%
2019 Q4	105.47 Million CNY	0.0%
2019 Q3	105.47 Million CNY	7.39%
2019 Q2	98.21 Million CNY	0.0%
2019 Q1	98.21 Million CNY	3.3%
2018 Q3	95.07 Million CNY	-30.07%
2018 Q4	95.07 Million CNY	0.0%
2018 Q1	135.95 Million CNY	-3.16%
2018 Q2	135.95 Million CNY	0.0%
2018 FY	462.06 Million CNY	2.09%
2017 Q1	115.83 Million CNY	0.75%
2017 FY	452.58 Million CNY	2.4%
2017 Q4	140.38 Million CNY	0.0%
2017 Q2	115.83 Million CNY	0.0%
2016 Q1	110.49 Million CNY	0.0%
2016 Q4	114.97 Million CNY	0.0%
2016 FY	441.98 Million CNY	19.9%
2016 Q2	110.49 Million CNY	0.0%
2015 FY	368.63 Million CNY	0.0%
2015 Q3	92.15 Million CNY	0.0%
2015 Q4	110.49 Million CNY	19.9%
2015 Q2	92.15 Million CNY	0.0%
2015 Q1	92.15 Million CNY	0.0%
2014 Q4	92.15 Million CNY	0.0%

Peer Revenue Comparison of Fusen Pharmaceutical Company Limited

Name	Revenue	Revenue Difference
Pak Fah Yeow International Limited	259.15 Million HKD	-118.248%
Grand Pharmaceutical Group Limited	10.52 Billion HKD	94.628%
Extrawell Pharmaceutical Holdings Limited	59.09 Million HKD	-857.068%
Wai Yuen Tong Medicine Holdings Limited	783.88 Million HKD	27.845%
Qianhai Health Holdings Limited	961.29 Million HKD	41.162%
Lee's Pharmaceutical Holdings Limited	1.05 Billion HKD	46.288%
Essex Bio-Technology Limited	1.7 Billion HKD	66.857%
Tongfang Kontafarma Holdings Limited	809.1 Million HKD	30.095%
PuraPharm Corporation Limited	406.85 Million HKD	-39.018%
SSY Group Limited	6.46 Billion HKD	91.249%
JBM (Healthcare) Limited	648.41 Million HKD	12.771%
Jacobson Pharma Corporation Limited	1.46 Billion HKD	61.466%
China Resources Pharmaceutical Group Limited	270.39 Billion HKD	99.791%